Why Novartis is a Top Value Stock for the Long-Term
| NVS Stock | USD 104.75 1.82 1.77% |
Slightly above 54% of Novartis' private investors are presently thinking to get in. The analysis of overall sentiment of trading Novartis AG ADR stock suggests that some investors are interested at this time. Novartis' investing sentiment can be driven by a variety of factors including economic data, Novartis' earnings reports, geopolitical events, and overall market trends.
Novartis |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why you should take advantage.
Read at finance.yahoo.com
 |
Novartis Fundamental Analysis
We analyze Novartis' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Novartis using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Novartis based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Probability Of Bankruptcy
Probability Of Bankruptcy Comparative Analysis
Novartis is currently under evaluation in probability of bankruptcy category among its peers. Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
Novartis AG ADR Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Novartis stock to make a market-neutral strategy. Peer analysis of Novartis could also be used in its relative valuation, which is a method of valuing Novartis by comparing valuation metrics with similar companies.
Peers
Novartis Related Equities
| SNY | Sanofi ADR | 3.84 | ||||
| RHHBY | Roche Holding | 2.55 | ||||
| LLY | Eli Lilly | 2.38 | ||||
| GILD | Gilead Sciences | 1.42 | ||||
| AZN | AstraZeneca PLC | 1.41 | ||||
| PFE | Pfizer | 1.09 | ||||
| GSK | GlaxoSmithKline PLC | 0.86 | ||||
| MRK | Merck | 0.68 | ||||
| JNJ | Johnson Johnson | 0.51 | ||||
| ABBV | AbbVie | 0.26 | ||||
| BMY | Bristol Myers | 0.15 |
Additional Tools for Novartis Stock Analysis
When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.